Smita Matkar

Smita Matkar

Auto-generated profile, based on publicly available information

Smita Matkar

Division of Oncology and Center for Childhood Cancer Research, The Children’s Hospital of Philadelphia, Philadelphia, Pennsylvania

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 July 2024 in Cancer Discovery
Verified
Journal Article
Open access
PDF file
LGLiron D. Grossmann
Liron D. Grossmann
CCChia-Hui Chen
Chia-Hui Chen
YUYasin Uzun
Yasin Uzun
ATAnusha Thadi
Anusha Thadi
AWAdam J Wolpaw
Adam J Wolpaw
JMJohn M. Maris
John M. Maris
Relapse rates in high-risk neuroblastoma remain exceedingly high. The malignant cells that are responsible for relapse have not been identified, and mechanisms of therapy resistance remain poorly understood. In this study, we used single-nucleus RNA sequencing and bulk whole-genome sequencing to identify and characterize the residual malignant persister cells that survive chemotherapy from a cohort of 20 matched diagnosis and definitive surgery tumor samples from patients treated with high-risk neuroblastoma induction chemotherapy. We show that persister cells share common mechanisms of chemotherapy escape, including suppression of MYC(N) activity and activation of NFκB signaling, and the latter is further enhanced by cell–cell communication between the malignant cells and the tumor microenvironment. Overall, our work dissects the transcriptional landscape of cellular persistence in high-risk neuroblastoma and paves the way to the development of new therapeutic strategies to prevent disease relapse. Significance: Approximately 50% of patients with high-risk neuroblastoma die of relapsed refractory disease. We identified the malignant cells that likely contribute to relapse and discovered key signaling pathways that mediate cellular persistence. Inhibition of these pathways and their downstream effectors is postulated to eliminate persister cells and prevent relapse. See related commentary by Wolf et al., p. 2308

5 February 2025 in Molecular Cancer Therapeutics
Verified
Journal Article
Open access
SMSmita Matkar
Smita Matkar
MEMichael P. East
Michael P. East
TSTimothy J. Stuhlmiller
Timothy J. Stuhlmiller
GWGabriela M. Witek
Gabriela M. Witek
AFAlvin Farrel
Alvin Farrel
YMYael P. Mossé
Yael P. Mossé
Mutations in the tyrosine kinase domain of the anaplastic lymphoma kinase (ALK) oncogene in neuroblastoma occur most frequently at one of three hotspot amino acid residues, with the F1174* and F1245* variants conferring de novo resistance to first- and second-generation ALK inhibitors, including crizotinib and ceritinib. Lorlatinib, a third-generation ALK/ROS1 inhibitor, overcomes de novo resistance and induces complete and sustained tumor regressions in patient-derived xenograft models unresponsive to crizotinib. Lorlatinib has now completed phase 1 testing in children and adults with relapsed/refractory ALK-driven neuroblastoma and entered pivotal phase 3 testing within the Children’s Oncology Group. To define mechanisms underlying the superior activity of lorlatinib, we utilized a chemical proteomics approach to quantitatively measure functional kinome dynamics in response to lorlatinib and crizotinib in clinically relevant ALK-driven neuroblastoma patient-derived xenograft models. Lorlatinib was a markedly more potent inhibitor of ALK and preferentially downregulated several kinases implicated in G2/M cell-cycle transition compared with crizotinib. Lorlatinib treatment also led to the repression of MYCN expression and its occupancy at promoters of the same G2/M kinases. These data provide mechanistic insight into the superior efficacy of lorlatinib over crizotinib for the treatment of ALK-driven neuroblastoma.

2 September 2025
Verified
Other
Open access
PDF file
SMSmita Matkar
Smita Matkar
MEMichael P. East
Michael P. East
TSTimothy J. Stuhlmiller
Timothy J. Stuhlmiller
GWGabriela M. Witek
Gabriela M. Witek
AFAlvin Farrel
Alvin Farrel
YMYael P. Mossé
Yael P. Mossé
Supplementary Table S2 shows oligonucleotide sequences of guide RNAs.

2 September 2025
Verified
Other
Open access
SMSmita Matkar
Smita Matkar
MEMichael P. East
Michael P. East
TSTimothy J. Stuhlmiller
Timothy J. Stuhlmiller
GWGabriela M. Witek
Gabriela M. Witek
AFAlvin Farrel
Alvin Farrel
YMYael P. Mossé
Yael P. Mossé
Mutations in the tyrosine kinase domain of the anaplastic lymphoma kinase (ALK) oncogene in neuroblastoma occur most frequently at one of three hotspot amino acid residues, with the F1174* and F1245* variants conferring de novo resistance to first- and second-generation ALK inhibitors, including crizotinib and ceritinib. Lorlatinib, a third-generation ALK/ROS1 inhibitor, overcomes de novo resistance and induces complete and sustained tumor regressions in patient-derived xenograft models unresponsive to crizotinib. Lorlatinib has now completed phase 1 testing in children and adults with relapsed/refractory ALK-driven neuroblastoma and entered pivotal phase 3 testing within the Children’s Oncology Group. To define mechanisms underlying the superior activity of lorlatinib, we utilized a chemical proteomics approach to quantitatively measure functional kinome dynamics in response to lorlatinib and crizotinib in clinically relevant ALK-driven neuroblastoma patient-derived xenograft models. Lorlatinib was a markedly more potent inhibitor of ALK and preferentially downregulated several kinases implicated in G2/M cell-cycle transition compared with crizotinib. Lorlatinib treatment also led to the repression of MYCN expression and its occupancy at promoters of the same G2/M kinases. These data provide mechanistic insight into the superior efficacy of lorlatinib over crizotinib for the treatment of ALK-driven neuroblastoma.

2 September 2025
Verified
Other
Open access
PDF file
SMSmita Matkar
Smita Matkar
MEMichael P. East
Michael P. East
TSTimothy J. Stuhlmiller
Timothy J. Stuhlmiller
GWGabriela M. Witek
Gabriela M. Witek
AFAlvin Farrel
Alvin Farrel
YMYael P. Mossé
Yael P. Mossé
Supplementary Figure S1 shows kinome remodeling in response to ALK inhibition is robust and heterogenous.

2 September 2025
Verified
Other
Open access
PDF file
SMSmita Matkar
Smita Matkar
MEMichael P. East
Michael P. East
TSTimothy J. Stuhlmiller
Timothy J. Stuhlmiller
GWGabriela M. Witek
Gabriela M. Witek
AFAlvin Farrel
Alvin Farrel
YMYael P. Mossé
Yael P. Mossé
Supplementary Table S5 shows RNA-seq p adjusted values of differentially expressed genes in COG-N-453x and NB-1643 tumor models comparing crizotinib vs lorlatinib treatment.